Description
The ACCeRT Study Auckland’s Cancer Cachexia evaluating Resistance Training Study A randomised feasibility study of EPA and Cox-2 inhibitor (Celecoxib) versus EPA, Cox-2 inhibitor (Celecoxib), Progressive Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic participantsAdditional information
_Cancer cachexia is a common problem in Non-Small Cell Lung Cancer (NSCLC). In cancer cachexia there is a significant loss of adipose tissue and skeletal muscle mass. There is a need to utilise a multi-targeted approach to decrease the inflammation process and stimulate the skeletal anabolic pathways with the use of progressive resistance training (PRT) and Essential Amino Acids (EAA).Methods_ ACCeRT is a randomised controlled feasibility, open-label study, investigating the acceptability, trends in efficacy and safety of a multi-targeted approach in end-stage NSCLCcachectic patients, over 20 weeks. Participants were randomised| Period | 2017 |
|---|---|
| Held at | The University of Auckland, New Zealand |
| Degree of Recognition | International |